Back

Alpha-1 adrenoreceptor antagonism mitigates extracellular mitochondrial DNA accumulation in lung fibrosis models and in patients with IPF

Ishikawa, G.; Peng, X.; McGovern, J.; Woo, S.; Perry, C.; Liu, A.; Yu, S.; Ghincea, A.; Sun, H.; Ryu, C.; Herzog, E. L.

2022-04-14 respiratory medicine
10.1101/2022.04.06.22273471 medRxiv
Show abstract

Idiopathic Pulmonary Fibrosis is increasingly associated with adrenergic innervation and endogenous innate immune ligands such as mitochondrial DNA (mtDNA). Interestingly, a connection between these entities has not been explored. Here we report that noradrenaline (NA) derived from the lungs adrenergic nerve supply drives the accumulation of SMA-expressing fibroblasts via a mechanism involving 1 adrenoreceptors and mtDNA. Using the bleomycin model of lung fibrosis we compared the effect of lung specific adrenergic denervation achieved via the inhalational administration of the sympathetic neurotoxin 6-hydroxydopamine to surgically mediated adrenal ablation and found that NA derived from local but not adrenal sources drives lung fibrosis. Bleomycin induced the appearance of a SMA+ fibroblast population co-expressing the adrenoreceptor alpha-1D (ADRA1D). Therapeutic delivery of the 1 adrenoreceptor antagonist terazosin reversed these changes and suppressed the accumulation of extracellular mtDNA. TGF{beta}1-stimulated normal human lung fibroblasts treated with TGF{beta}1 and Noradrenaline expressed ADRA1D and developed reduced SMA expression and extracellular mtDNA concentrations when treated with terazosin. IPF patients prescribed 1 adrenoreceptor antagonists for non-pulmonary indications showed improved survival and reduced concentrations of plasma mtDNA. These findings link nerve-derived NA and 1 adrenoreceptor antagonism with mtDNA accumulation and lung fibrogenesis in mouse models, cultured cells, and humans with IPF. Further study of this neuro-innate connection may yield new avenues for investigation in the clinical and basic science realms.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
American Journal of Respiratory Cell and Molecular Biology
43 papers in training set
Top 0.1%
26.6%
2
JCI Insight
277 papers in training set
Top 0.1%
15.1%
3
European Respiratory Journal
59 papers in training set
Top 0.1%
12.7%
50% of probability mass above
4
American Journal of Physiology-Lung Cellular and Molecular Physiology
43 papers in training set
Top 0.1%
11.9%
5
Respiratory Research
21 papers in training set
Top 0.1%
6.8%
6
American Journal of Respiratory and Critical Care Medicine
43 papers in training set
Top 0.2%
5.5%
7
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 19%
2.8%
8
ERJ Open Research
47 papers in training set
Top 0.4%
1.7%
9
BMJ Open Respiratory Research
35 papers in training set
Top 0.4%
1.4%
10
Arthritis & Rheumatology
36 papers in training set
Top 0.4%
1.3%
11
The American Journal of Pathology
32 papers in training set
Top 0.5%
1.1%
12
Frontiers in Cell and Developmental Biology
233 papers in training set
Top 4%
0.9%
13
Thorax
35 papers in training set
Top 0.7%
0.8%
14
Scientific Reports
3612 papers in training set
Top 74%
0.8%
15
Frontiers in Immunology
638 papers in training set
Top 9%
0.8%
16
iScience
1154 papers in training set
Top 34%
0.8%
17
Pulmonary Circulation
10 papers in training set
Top 0.3%
0.8%
18
PLOS ONE
5266 papers in training set
Top 64%
0.6%
19
Journal of Cachexia, Sarcopenia and Muscle
33 papers in training set
Top 0.7%
0.6%